CRF Health Announces Global Partnership with Vodafone
Plymouth Meeting, PA – February 17, 2015: CRF Health, the leading global provider of electronic Clinical Outcome Assessment (eCOA) solutions for the life sciences industry, today announced a new partnership with Vodafone. CRF Health will use Vodafone’s global Machine-to-Machine (M2M) platform to offer an enhanced service to clinical trial operators and their patients.
As a result of the partnership, managing mobile data sending in clinical studies using the TrialMax® eCOA platform is made significantly easier and more predictable for CRF Health clients. The agreement provides clinical trial sponsors running global studies with assured connectivity and instant access to data through Vodafone’s global network. Reliability, security and integration are crucial to ensure that healthcare industry requirements and standards are met.
“Having a trusted communications services partner is critical for us", comments CRF Health’s Vice President of Contracts and Vendor Management, Jaime Racine. She continues, "Partnering with Vodafone will help us provide our clients with more predictable data sending while improving the quality of our products and services”.
Vodafone Group’s Head of Machine-to-Machine Sales for Northern Europe, Cyril Deschanel, said, “Our global M2M platform and services allow CRF Health to confidently provide customers with reliable global end-to-end solutions for clinical trials to ensure the highest quality outcomes. Working together with CRF Health, we can achieve their goal of a seamless global experience and greater operational efficiency.”
For further information on CRF Health, please visit www.crfhealth.com
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
